Background Direct oral anticoagulants (DOAC s) are noninferior to warfarin for stroke
prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Aims: Observational studies of various dose levels of direct oral anticoagulants (DOACs) for
patients with atrial fibrillation (AF) found that a high proportion of patients received a dose …

BACKGROUND: Direct oral anticoagulants (DOACs) have become widely used for the
prevention of stroke in nonvalvular atrial fibrillation (AF) and for the treatment of venous …

Background—Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest
benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been …

Background: In the clinical setting, the economic benefits of direct oral anticoagulants
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …

Background: The use of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) and
low stroke risk might cause more harm than benefit. Little attention has been given to …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …